AE Measures Offer Insights for Endocrine Therapy Discontinuation in DCIS


Assessing adverse effects with a toxicity index and patient-reported outcomes at baseline and treatment-emergent toxicities revealed insights into why postmenopausal patients with ductal carcinoma in situ discontinued endocrine therapy.

An analysis of the adverse effect (AE) profiles of postmenopausal patients with ductal carcinoma in situ using the toxicity index revealed insights into the reasons for discontinuation of endocrine therapy, which were further enhanced by patient-reported outcomes (PROs) measured at baseline and treatment-emergent toxicities, according to results from a study published in the Journal of Clinical Oncology.

When investigators examined baseline PROs and AEs that occurred during treatment, they reported that thrombosis and arthralgia were the AEs most commonly associated with discontinuation of treatment with tamoxifen and anastrozole. Other factors such as baseline pain interference, hot flashes, and unhappiness were associated with discontinuation of tamoxifen (overall Harrell's C-statistic, 0.686; 95% CI, 0.640-0.732), although no baseline factors were associated with anastrozole discontinuation (overall Harrell's C-statistic, 0.656, 95% CI, 0.630-0.681). Baseline PROs associated with a shorter time to discontinuation included pain interference, hot flashes, and unhappiness in the tamoxifen arm and hot flashes in the anastrozole arm.

“This analysis of clinician-reported AEs using the Toxicity Index method yielded important insights into reasons for endocrine therapy discontinuation in patients without prior chemotherapy treatment,” the investigators wrote. “Patient-reported symptoms measured before and during treatment further enhanced this understanding.”

Available toxicity data were drawn from the phase 3 NSABP B-35 clinical trial (NCT00053898). In the study, patients were randomly assigned 1:1 to receive either tamoxifen at 20 mg orally once daily plus an identical placebo or anastrozole at 1 mg orally once daily plus an identical placebo for tamoxifen. Patients were stratified by age (younger than 60 years vs 60 years or older).

The primary end point was time to treatment discontinuation, which was defined as the date of first treatment to the date treatment was discontinued.

A total of 3046 patients were available for analysis, of whom half were assigned to tamoxifen (n = 1523) and the other to anastrozole (n = 1523). A total of 28.5% of patients prematurely discontinued treatment. Specifically, 28.2% receiving tamoxifen and 28.9% receiving anastrozole discontinued treatment. Focusing on the time-dependent covariate, toxicity was associated with discontinuations for both tamoxifen (HR, 1.77; 95% CI, 1.65-1.90) and anastrozole (HR, 1.71; 95% CI, 1.60-1.83). Median age was 60 years (range, 55-66) and 84.9% of the population was non-Hispanic White.

A multivariable analysis found that higher Toxicity Index values for blood or bone marrow, general cardiovascular, constitutional symptoms, hepatic, neurology, and pain domains were all significantly associated with shorter time to discontinuation for patients receiving tamoxifen (Harrell’s C-statistic, 0.675; 95% CI, 0.656-0.693). For patients who received anastrozole, increased toxicity index value of general cardiovascular, constitutional, dermatology, neurology, and pain domains were significantly associated with a shorter time to discontinuation (Harrell’s C-statistic, 0.671; 95% CI, 0.652-0.690).

AEs associated with treatment discontinuations in both treatment groups included fatigue, arthralgia, myalgia, sensory neuropathy, and cardiac ischemia. For patients treated with tamoxifen, additional symptoms associated with time to discontinuations included thrombosis, nausea, transaminitis, dizziness, chest pain, and headache. For anastrozole, those AEs included anorexia, cerebrovascular ischemia, pruritus, and bone pain.

A total of 1185 patients had baseline PRO data, including 596 patients in the tamoxifen arm and 589 in the anastrozole arm. In the tamoxifen arm, worse physical health, depression scores at baseline, and multiple AEs were significantly associated with a shorter time to treatment discontinuation.

“This approach to assessment of treatment tolerability should be considered both when analyzing and interpreting data from previously conducted randomized controlled trials and when designing prospective studies examining new treatment interventions for patients with cancer,” the investigators concluded.


Henry NL, Kim S, Hays RD, et al. Toxicity Index, Patient-reported outcomes, and early discontinuation of endocrine therapy for breast cancer risk reduction in NRG Oncology/NSABP B-35. J Clin Oncol. 2021;39(34):3800-3812. doi:10.1200/JCO.21.00910

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content